The INHALE-1 trial evaluated inhaled technosphere insulin in children. While it narrowly missed the primary HbA1c noninferiority margin, the study demonstrated improved patient satisfaction, reduced weight gain, and a favorable safety profile, suggesting its potential as a needle-free alternative for select pediatric patients.